Which biotherapy agent is commonly used in the treatment of melanoma?

Ipilimumab is a biotherapy agent that plays a significant role in treating melanoma. It is a monoclonal antibody that targets and inhibits CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), a protein receptor that downregulates the immune system. By blocking CTLA-4, ipilimumab enhances the activation and proliferation of T-cells, which are critical for the immune response against cancer cells. This mechanism of action allows the immune system to effectively recognize and attack melanoma cells.

Staging and treatment plans for melanoma have evolved, but the introduction of ipilimumab has contributed greatly to the shift toward using immunotherapy. It is often utilized in combination with other agents to improve overall efficacy. While other agents like nivolumab, also a checkpoint inhibitor, are involved in melanoma treatment strategies, ipilimumab is distinctly known for its specific mechanism related to CTLA-4 inhibition. Understanding these different agents and their mechanisms is crucial in oncology nursing and treatment planning for patients with melanoma.